26th Mar 2014 13:36
VERONA PHARMA PLC - Holding(s) in CompanyVERONA PHARMA PLC - Holding(s) in Company
PR Newswire
London, March 26
For filings with the FCA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached:ii 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights V An acquisition or disposal of qualifying financial instruments which may resultin the acquisition of shares already issued to which voting rights are attached An acquisition or disposal of instruments with similar economic effect toqualifying financial instruments An event changing the breakdown of voting rights Other (please specify): 3. Full name of person(s) subject to the Vivo Ventures Fund VII, LPnotification obligation:iii 4. Full name of shareholder(s) Vivo Ventures fund VII, LP (if different from 3.):iv 5. Date of the transaction and date onwhich the threshold is crossed or March 25, 2014reached: v 6. Date on which issuer notified: March 25, 2014 7. Threshold(s) that is/are crossed or 3%reached: vi, vii 8. Notified details: A: Voting rights attached to shares viii, ix Class/type Situation previous Resulting situation after the triggering transactionof to the triggeringshares transaction if possible Number Number Number Number of voting % of voting rights xusing of of of shares rightsthe ISIN Shares VotingCODE Rights Direct Direct xi Indirect xii Direct Indirect GB00B06GSH43 64,200,753 6.66% B: Qualifying Financial Instruments Resulting situation after the triggering transaction Type of financial Expiration Exercise/ Number of voting % of votinginstrument date xiii Conversion Period xiv rights that may be rights acquired if the instrument is exercised/ converted. C: Financial Instruments with similar economic effect to Qualifying FinancialInstruments xv, xvi Resulting situation after the triggering transaction Type of Exercise price Expiration Exercise/ Number of voting rights % of voting rightsfinancial date xvii Conversion period instrument refers to xix, xxinstrument xviii Nominal Delta Total (A+B+C) Number of voting rights Percentage of voting rights 64,200,753 6.66% 9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi Vivo Ventures Fund VII, LP is a limited partnership formed in Delaware, USA.Vivo Ventures VII, LLC is its General Partner. Vivo Ventures Fund VII, LP owns64,200,753 shares of common stock of the issuer. Proxy Voting: 10. Name of the proxy holder: 11. Number of voting rights proxy holder will ceaseto hold: 12. Date on which proxy holder will cease to holdvoting rights: 13. Additional information: 14. Contact name: 15. Contact telephone number:
Related Shares:
VRP.L